MARKET WIREYahoo Finance Australia • 10h ago
ImmunityBio, Inc. (IBRX) stock price, news, quote and historyYahoo Finance Australia report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
Why IBRX Stock dropped -5.15% Today — RQD Quant Desk Flash
$8.29 -5.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $8.20
ImmunityBio Inc. (IBRX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $9.26B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IBRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, ImmunityBio Inc. (NASDAQ: IBRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $8.29 (-5.15% 1D, market cap $9.26B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, IBRX ranks #599 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IBRX compare to KRYS and PCVX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IBRX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -27.3%. By comparison, KRYS (Krystal Biotech Inc.) holds a B grade (72/100 RQD, P/E 46.9x, ROIC 16.5%, cap $9.61B) and PCVX (Vaxcyte Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC -27.6%, cap $9.85B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IBRX?
▼
Per IBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326110), ImmunityBio Inc. generated $113.3M in revenue (+668.3% YoY), -$351.5M in net income, and -$308.8M in free cash flow against $501.9M in total assets and $450.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $8.20 (-1.12%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IBRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY IBRX SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (30% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)
FRED Regime × Technicals: 60% of 52W Range • RSI-14 at 49 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$9.80-10.5% Next Q
45
Q2 (-2Q)Grade D$8.77-1.6% Next Q
42
Q3 (-1Q)Grade D$8.63-3.9% Next Q
40
CurrentGrade D-$8.29-8.1% Hist 90D α
37
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IBRX Turnaround Squeeze
While IBRX currently carries a cautious 37/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.75) and Max Pain ($8.70) forces dealer call-delta covering toward $13.05.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IBRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IBRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IBRX Stock dropped -5.15% Today — RQD Quant Desk Flash
ImmunityBio Inc. (IBRX) dropped -5.15% to $8.29, trading at 60% of its 52-week range ($1.95 – $12.43). Stretched risk/reward at current multiples (-27% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 60% of its 52-week range ($1.95 – $12.43) with RSI-14 at 49 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $8.29 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 99.3% gross margin and $0 annual free cash flow.
Live IBRX Headlines & Catalysts
MARKET WIRECNN • 13h ago
symbol__ Stock Quote Price and ForecastCNN report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 16h ago
Immunitybio Inc Stock (IBRX) Moved Up by 8.17% on Oct 9: Drivers Behind the MovementTradingKey report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 19h ago
ImmunityBio Inc (IBRX) Stock Price, Quote, News & HistoryBenzinga report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREKavout • 22h ago
Should I Buy IBRX (ImmunityBio, Inc.) | AI Analysis, Technical & News InsightsKavout report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover WaveTradingView report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
ImmunityBio (IBRX) Could Be 33% Undervalued Following Its Ottawa Symposium UpdateYahoo Finance report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
ImmunityBio (NasdaqGS:IBRX) Stock Forecast & Analyst PredictionsSimply Wall St report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 20h ago
SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In FocusAstraZeneca emphasized ADC combinations, cell therapies and internally developed cancer vaccines as key oncology priorities.
MARKET WIREYahoo • 3d ago
SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IBRX)
- ✓Walkthrough of IBRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IBRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.57%▲ ASCENDING CHANNEL
2026-11-02O $8.81H $8.81L $8.29C $8.29VOL 7.15M
RES: $11.20SUP: $7.85SMA50: $8.75SMA200: $7.94
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IBRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
22.3%/yr Implied 5Y Growth
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IBRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IBRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IBRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IBRX)
Health Care Rank #599 of 1016
⚔️ KRYS vs IBRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IBRX vs. KRYS, PCVX, KYMR, QGEN)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ImmunityBio Inc. (IBRX) ranks #599 by composite RQD confidence (37/100, grade D-) and #122 by equity capitalization ($9.26B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and — gross margin. KRYS currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with IBRX at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IBRX
ACTIVE
ImmunityBio Inc. | D- | 37/100 | — | 96.0% | -27.3% | -5.15% | $9.26B | Benchmark Subject |
| KRYS Krystal Biotech Inc. | B | 72/100 | 46.9x | — | 16.5% | +2.38% | $9.61B | /krys-vs-ibrx → |
| PCVX Vaxcyte Inc. | D | 49/100 | — | — | -27.6% | -0.93% | $9.85B | /pcvx-vs-ibrx → |
| KYMR Kymera Therapeutics Inc. | D | 50/100 | 32.7x | — | -21.4% | +3.29% | $10.19B | /kymr-vs-ibrx → |
| QGEN Qiagen N.V. | B- | 71/100 | 24.4x | 62.2% | 8.0% | -0.24% | $10.37B | /qgen-vs-ibrx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001326110In its most recent audited fiscal period (FY2025, filed 2025-12-31), ImmunityBio Inc. (IBRX) reported GAAP revenue of $113.3M (+668.3% vs. FY2024 revenue of $14.7M , and +18113.5% cumulative change since FY2023) , GAAP net income of -$351.5M, operating cash flow of -$304.9M, and free cash flow of -$308.8M (+22.4% YoY). On the balance sheet, IBRX closed FY2025 with $501.9M in total assets against $450.7M in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $113.3M | -$351.5M | -$304.9M | -$308.8M | $501.9M | $450.7M |
| FY2024 (FY) | 2024-12-31 | $14.7M | -$413.6M | -$391.2M | -$398.1M | $382.9M | $392.0M |
| FY2023 (FY) | 2023-12-31 | $622.0K | -$583.9M | -$366.8M | -$366.8M | $5.09B | $1.19B |
3. IBRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, ImmunityBio Inc. (NASDAQ: IBRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $8.29 (-5.15% 1D, market cap $9.26B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, IBRX ranks #599 in composite RQD confidence.
How does IBRX compare to KRYS and PCVX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IBRX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -27.3%. By comparison, KRYS (Krystal Biotech Inc.) holds a B grade (72/100 RQD, P/E 46.9x, ROIC 16.5%, cap $9.61B) and PCVX (Vaxcyte Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC -27.6%, cap $9.85B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IBRX?
Per IBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326110), ImmunityBio Inc. generated $113.3M in revenue (+668.3% YoY), -$351.5M in net income, and -$308.8M in free cash flow against $501.9M in total assets and $450.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IBRX trading relative to its 50-day, 200-day, and 52-week technical levels?
IBRX last traded at $8.29 (-5.15% on volume of 8,960,512 shares), positioning the stock -5.26% below its 50-day simple moving average ($8.75) and +4.41% above its 200-day simple moving average ($7.94). Across its 52-week range of $1.95 to $12.43, IBRX sits at the 60.5% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.25 to $9.33).
IBRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IBRX stock moving today?
Why IBRX Stock dropped -5.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-27% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 37/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
IBRX — ImmunityBio Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:17:06Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, IBRX scores 37 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The fundamental cash engine pillar scores 4 out of 20, reflecting ROIC of -27.3% and an FCF yield of -3.33%; this is the weakest pillar and indicates the business is not currently converting capital into returns. The whale 13F flow pillar scores 11 out of 20, reflecting institutional accumulation and options positioning as a relative strength. The insider conviction pillar scores 5 out of 20, covering SEC Form 4 and Congressional PTR cluster flow, which the rating treats as weak. The macro regime fit pillar scores 9 out of 20, with a beta of 1.05 and sector sensitivity noted. The forensic balance sheet pillar scores 8 out of 20, drawing on an Altman Z-Score of 0.45, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.85.
For a prospective investor evaluating the stock today, the rating's implication is that valuation rests on future cash generation rather than current earnings, since reported EPS (TTM) is -0.33 and operating margin is -60%. Upside drivers cited in the data are institutional positioning and recent positive price action; the principal tradeoff is the forensic weakness in the balance sheet and negative cash flow. Investors weighing this name would be accepting elevated balance-sheet risk in exchange for exposure to a high-volatility biotech profile.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $113.3M | $-256.0M | $-351.5M | N/A | $-308.8M | $88.3M | $450.7M |
| FY 2024 | $14.7M | $-344.2M | $-413.6M | N/A | $-398.1M | $143.4M | $392.0M |
| FY 2023 | $0.6M | $-362.2M | $-583.9M | N/A | $-366.8M | N/A | $1192.1M |
Reported revenue rose from $0.6M in FY 2023 to $113.3M in FY 2025, while net income remained negative in every period shown, with gross margin at 96% and operating margin at -60% per the market data. Per the Roarable RQD rating, ROIC is -27.3% and the forensic pillar cites an Altman Z-Score of 0.45 and a Piotroski F-Score of 6/9. Debt/Equity is 0.85 per the rating, and reported debt declined from $1192.1M in FY 2023 to $450.7M in FY 2025 while cash fell from $143.4M to $88.3M over the FY 2024–FY 2025 span.
Open Questions
- What is the company's specific product portfolio and revenue composition behind the FY 2025 revenue of $113.3M?
- What drove the 8.17% move on Oct 9 and the overnight rise referenced in the news wire?
- What is the debt maturity schedule and covenant structure behind the reported debt of $450.7M?
- What is the basis for the forward P/E of 29 given negative EPS and operating losses?
- What is the trailing P/E and EV/EBITDA, which the source data does not provide?
IBRX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for ImmunityBio Inc. (IBRX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance Australia • 10h ago
ImmunityBio, Inc. (IBRX) stock price, news, quote and history Yahoo Finance Australia report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE CNN • 13h ago
symbol__ Stock Quote Price and Forecast CNN report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 16h ago
Immunitybio Inc Stock (IBRX) Moved Up by 8.17% on Oct 9: Drivers Behind the Movement TradingKey report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 19h ago
ImmunityBio Inc (IBRX) Stock Price, Quote, News & History Benzinga report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Kavout • 22h ago
Should I Buy IBRX (ImmunityBio, Inc.) | AI Analysis, Technical & News Insights Kavout report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave TradingView report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
ImmunityBio (IBRX) Could Be 33% Undervalued Following Its Ottawa Symposium Update Yahoo Finance report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
ImmunityBio (NasdaqGS:IBRX) Stock Forecast & Analyst Predictions Simply Wall St report covering ImmunityBio Inc. (IBRX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IBRX Bull vs. Bear Conversation Board — What's Your Call at $8.29?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IBRX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $7.69 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is IBRX (D- • RQD 37/100) a Buy at $8.74?
Welcome to the IBRX (ImmunityBio Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $6.73 (-23.0%)
Spot @ $8.74 Pump the brakes on IBRX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on IBRX, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless ImmunityBio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $11.01 (+26.0%)
Spot @ $8.74 IBRX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on IBRX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $8.74 (52-wk range $1.95 - $12.43), any beat on forward guidance forces shorts and underweight funds to chase.